Gut germs may hold key to fighting superbug blood infections in COVID patients

NCT ID NCT07183722

Ongoing Knowledge-focused Sponsor: Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study looks at how the gut microbiome influences the risk of blood infections (bacteremia) in adults hospitalized with COVID-19. Researchers will analyze stool samples from 86 patients in intensive care and internal medicine units using advanced genetic sequencing. The goal is to understand why some people develop dangerous antibiotic-resistant infections and how to better detect and prevent them.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could improve how we detect and track antibiotic-resistant infections, leading to better treatment strategies.
What could go wrong: This is an observational study, not a treatment trial. It will not directly benefit participants, and results may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MICROBIOTA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MICROBIOTA

Contacts and locations

Locations

SSD Laboratori di Ricerca (DAIRI) - AOU Alessandria

Alessandria, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.